Abstract

M. Navya Sai*, Dr. K. Tirumala Naik, M. R. B. Vidya Sree, M. Prathyusha Bai, S. Zeenath, S. Ajay Kumar

ABSTRACT

Clindamycin, a broad-spectrum antibiotic, is commonly prescribed for the treatment of various bacterial infections. However, its use can be associated with adverse effects, including antibiotic-associated diarrhea and disruption of the natural gut microbiota. It exhibits potent antimicrobial activity against susceptible bacteria but also indiscriminately targets beneficial gut bacteria, leading to dysbiosis and the overgrowth of opportunistic pathogens such as Clostridium difficile. Lactic acid bacillus, a type of probiotic bacterium, has been extensively studied for its ability to restore and maintain a healthy gut microbiota. By supplementing clindamycin therapy with lactic acid bacillus, the aim is to minimize the disruption of the gut microbiome and potentially reduce the incidence of adverse gastrointestinal effects. Studies evaluating the concomitant use of clindamycin and lactic acid bacillus have demonstrated promising outcomes. Lactic acid bacillus has been shown to reduce the risk of antibiotic-associated diarrhea and C. difficile infection by preventing the colonization of pathogenic bacteria and enhancing the restoration of the intestinal flora. In conclusion, the concomitant use of clindamycin and lactic acid bacillus presents a potential strategy to mitigate antibiotic-induced gastrointestinal disturbances and restore microbial balance. This approach holds promise in reducing the incidence of antibiotic-associated diarrhea and C. difficile infection. However, careful consideration of dosage, patient selection, and long-term effects is necessary to fully understand the clinical implications and maximize the benefits of this therapeutic combination.